PRAX Praxis Precision Medicines Inc.

14.23
-0.59  -4%
Previous Close 14.82
Open 14.65
52 Week Low 14.06
52 Week High 60.9505
Market Cap $550,196,091
Shares 38,664,518
Float 22,979,397
Enterprise Value $332,933,480
Volume 138,343
Av. Daily Volume 334,018
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
PRAX-944
Essential tremor
Phase 2a
Phase 2a
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
PRAX-562
Healthy volunteers
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
PRAX-114
Major Depressive Disorder and perimenopausal depression
Phase 2a
Phase 2a
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
PRAX-114 Aria Study (Study 213)
Major Depressive Disorder
Phase 2/3
Phase 2/3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
PRAX-114 (Study 214)
Major depressive disorder
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
PRAX-114
Essential Tremor
Phase 2a
Phase 2a
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
PRAX-562
Developmental epileptic encephalopathies (DEEs)
Phase 2
Phase 2
Phase 2 trial to be initiated 1H 2022.
PRAX-944
Parkinson’s disease
Phase 2
Phase 2
Phase 2 trial to be initiated 1H 2022.

Latest News

  1. CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 9:10 a.m. ET.

    The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.

    About Praxis
    Praxis…

    CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 9:10 a.m. ET.

    The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.

    About Praxis

    Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.



    Investor Contact:
    Alex Kane
    Praxis Precision Medicines
    
    617-300-8481
    
    Media Contact:
    Ian Stone
    Canale Communications
    
    619-849-5388

    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

    • Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
      Fireside chat on Tuesday, July 13, 2021 at 3:00 p.m. ET
    • William Blair Biotech Focus Conference 2021
      ‘Updates in Neuropsych' panel on Thursday, July 15, 2021 at 12:00 p.m. ET

    The events will be available via webcast through the Events & Presentations page of the Investors + Media section of the company's…

    CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

    • Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

      Fireside chat on Tuesday, July 13, 2021 at 3:00 p.m. ET
    • William Blair Biotech Focus Conference 2021

      ‘Updates in Neuropsych' panel on Thursday, July 15, 2021 at 12:00 p.m. ET

    The events will be available via webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com. Replays of the webcasts will be available for 90 days following the events.

    About Praxis

    Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.



    Investor Contact:
    Alex Kane
    Praxis Precision Medicines
    
    617-300-8481
    
    Media Contact:
    Ian Stone
    Canale Communications
    
    619-849-5388

    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Marcio Souza to its board of directors. Mr. Souza serves as the president & chief executive officer of Praxis Precision Medicines, Inc. (NASDAQ:PRAX).

    "On behalf of the Aeglea family, I'm pleased to warmly welcome Marcio to our board of directors. We are at a pivotal stage of the company's growth and it is important to have a breadth of experience and diversity of perspectives as we navigate the transition to becoming a commercial-stage company," said Anthony Quinn, M.B Ch.B…

    AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Marcio Souza to its board of directors. Mr. Souza serves as the president & chief executive officer of Praxis Precision Medicines, Inc. (NASDAQ:PRAX).

    "On behalf of the Aeglea family, I'm pleased to warmly welcome Marcio to our board of directors. We are at a pivotal stage of the company's growth and it is important to have a breadth of experience and diversity of perspectives as we navigate the transition to becoming a commercial-stage company," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Marcio brings extensive global operating and commercial experience, with notable expertise in regions outside of the United States and a proven track record in the rare disease space. The insights and perspectives that Marcio brings to the team will be invaluable in shaping the global commercialization strategy for our portfolio of rare metabolic disease treatments."

    "I'm excited to be joining the board of Aeglea, a company committed to having a transformative impact on the lives of patients with rare metabolic diseases," said Mr. Souza. "With Phase 3 data from the Arginase 1 Deficiency program coming in the fourth quarter of 2021 and a second program for Homocystinuria entering the clinic, Aeglea is a company with considerable potential and I look forward to working with the team to bring it to fruition."

    Prior to joining Praxis Precision Medicines, Mr. Souza served as chief operating officer at PTC Therapeutics, Inc. from May 2017 to April 2020 and its senior vice president and head of product strategy from July 2016 to May 2017. Previously, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. He also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.

    About Aeglea BioTherapeutics

    Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in 2020. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

    Safe Harbor / Forward Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our ability to obtain regulatory approval for, and commercialize, pegzilarginase, recognize milestone and royalty payments from our agreement with Immedica, the potential addressable markets of our product candidates, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, our cash forecasts, and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    (PRNewsfoto/Aeglea BioTherapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-appoints-marcio-souza-to-board-of-directors-301316976.html

    SOURCE Aeglea BioTherapeutics, Inc.

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced the appointment of Tim Kelly as chief financial officer, effective immediately. Mr. Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and head of corporate management.

    "Tim's diverse background and leadership experience in finance, strategy and business operations roles make him an ideal chief financial officer for Praxis and our needs moving forward," said Marcio Souza, president and chief executive officer…

    CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced the appointment of Tim Kelly as chief financial officer, effective immediately. Mr. Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and head of corporate management.

    "Tim's diverse background and leadership experience in finance, strategy and business operations roles make him an ideal chief financial officer for Praxis and our needs moving forward," said Marcio Souza, president and chief executive officer of Praxis. "Praxis is well capitalized following the recently completed equity financing, and Tim's stewardship will ensure that that we remain prudent and strategic as our pipeline continues to progress and expand."

    Mr. Kelly added, "This is an exciting time to be joining Praxis, with an incredibly deep pipeline of CNS drug candidates, a wealth of upcoming milestones and the capital needed to execute on the company's strategic objectives. I look forward to working closely with the team to help Praxis achieve its strategic and financial goals."

    Mr. Kelly brings more than 20 years of experience in the life sciences, pharmaceutical and biotechnology industries. Most recently, Mr. Kelly was the chief financial officer and head of corporate management at Foundation Medicine, having served in this role since 2019. In this position, he led the finance and corporate management teams, providing strategic leadership and oversight for the corporate functions, which included accounting and tax, billing and reimbursement, corporate development, project management and financial planning and analysis. Prior to working at Foundation Medicine, Mr. Kelly worked at the Roche Group for more than 15 years, serving in finance roles of increasing responsibility across product commercialization, pipeline development, manufacturing and strategic planning, most recently as the finance and corporate services director for Roche Pharma in the UK. Mr. Kelly holds a bachelor of arts in economics from the College of William and Mary, and a master's in business administration from the Columbia Business School.

    About Praxis

    Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.



    Investor Contact:
    Alex Kane
    Praxis Precision Medicines
    
    617-300-8481
    
    Media Contact:
    Ian Stone
    Canale Communications
    
    619-849-5388

    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

    • RBC Capital Markets Global Healthcare Conference
      Presentation on Wednesday, May 19, 2021 at 2:30 p.m. ET
    • Oppenheimer Rare & Orphan Disease Summit
      Prerecorded presentation available on Friday, May 21, 2021 at 8:00 a.m. ET

    The events will be available via webcast through the Events & Presentations page of the Investors + Media section of the company's website at…

    CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

    • RBC Capital Markets Global Healthcare Conference

      Presentation on Wednesday, May 19, 2021 at 2:30 p.m. ET
    • Oppenheimer Rare & Orphan Disease Summit

      Prerecorded presentation available on Friday, May 21, 2021 at 8:00 a.m. ET

    The events will be available via webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com. Replays of the webcasts will be available for 90 days following the events.

    About Praxis

    Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.



    Investor Contact:
    Alex Kane
    Praxis Precision Medicines
    
    617-300-8481
    
    Media Contact:
    Ian Stone
    Canale Communications
    
    619-849-5388

    Primary Logo

    View Full Article Hide Full Article
View All Praxis Precision Medicines Inc. News